ReNAgade Therapeutics, a cutting-edge biotechnology company dedicated to pioneering RNA medicines, has successfully raised $300 million in its latest funding round. This significant investment will propel the company's mission to unlock the full potential of RNA-based therapies, enabling transformative treatments for diseases across various tissues and organs. At the forefront of innovation, ReNAgade merges its groundbreaking RNA delivery platforms with a comprehensive RNA system designed for coding, editing, and gene insertion. This all-RNA approach positions the company uniquely within the biotech landscape, facilitating the development of next-generation medicines that were previously thought to be unattainable. With a team brimming with expertise in RNA therapeutics and advanced delivery methodologies, ReNAgade is poised to challenge existing paradigms in medicine, making RNA therapies more accessible and effective. The funding will specifically focus on accelerating ongoing clinical programs and expanding research initiatives that explore new avenues for RNA applications in treating serious medical conditions. As the world increasingly turns to genomic and RNA science for solutions to complex health challenges, ReNAgade Therapeutics stands out as a leader in this transformative field. With a bold vision and robust financial backing, ReNAgade is committed to pioneering RNA therapies that could redefine the treatment landscape, living up to its inspiring tagline—RNA Without Limits. This latest funding round marks a significant milestone in the company’s journey, underscoring investor confidence in its potential to revolutionize healthcare through innovative biologic therapies.
ReNAgade Therapeutics Secures $300 Million in Funding to Revolutionize RNA Medicines
Get the full ReNAgade Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Maneva
Maneva AI revolutionizes manufacturing by offering a superhuman digital workforce tailored to the industry's unique needs. Our AI empowers factories to streamline operations, cut costs, and enhance productivity. Designed specifically for manufacturing, Maneva AI delivers a range of benefits, from reducing labor dependencies and enhancing quality assurance to eliminating downtime and preserving critical knowledge. Our seamless implementation ensures swift integration into existing workflows, guaranteeing remarkable returns on investment for manufacturers across America. Even tasks once deemed unautomatable are effortlessly handled by Maneva AI. Many challenges facing manufacturing companies, too intricate for costly automation projects, find solutions in our intelligent systems. Leveraging manufacturing-specific intelligence, Maneva AI consistently proves its efficacy, bringing companies closer to a future-proof state. Experience tangible, profitable, and tactical results with Maneva AI. Reach out now to discover how we can drive immediate impact for your business!
$27.0M Series a
today
Avon Health
Avon Health is powering next-gen healthcare. The Avon EMR is an AI-forward, infinitely customizable EMR to power next-gen care delivery practices, from solo primary clinics with 400 patients to virtual care companies with 100,000+ patients. Our customizable modules and APIs have enabled care delivery companies to customize their EMR and patient engagement platform in days, complete with functionality to treat patients in-person and virtually, bill insurance, automatically scribe medical notes using AI, automate workflows, and more.
$9.0M Seed
today
Wassist
The WhatsApp Agents Platform. Engage customers where they already chat. Hyper-personalized conversations with no invasive tracking, where you can checkout in your chat.
$1.1M Seed
today
Cordon Technologies
The world is in the middle of an AI and Robotics revolution. Cordon is bringing this to vineyards, reducing costs and allowing better, more sustainable farming. We are farmers ourselves. Cordon's solutions are reliable, robust, cost effective, and integrate seamlessly with your current machinery and day to day operations.
$1.3M Seed
today
Infinity Constellation
Infinity Constellation is the first AI services holding company, building category leaders designed to displace incumbents in the $9T+ professional services market. We give exceptional operators a 12-month head start—backed by capital, shared infrastructure, customers, back-office support, and shared equity—to launch outcome-driven businesses that redefine their industries.
$24.0M Series a
today